Home > News

Autorizzo al trattamento dei miei dati personali
ai sensi del D.L. 30 giugno 2003 n. 196
Edit email address
Invalid email
Your request has been sent successfully
Authorize the processing of personal data
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
17:44
ARCHIVE NEWS
Chiesi Farmaceutici S.p.A. has obtained ISO 37001:2016 certification for its Anti-Bribery Management System
Chiesi Achieves Platinum Medal from EcoVadis
Chiesi’s investment in women equal pay achieves the Fair Pay certification
Empowering Women in Science and Healthcare: Chiesi’s Commitment to Gender Equality
Taking a Stand: Our Global Commitment Against Workplace Harassment and Violence
Chiesi awarded with Great Place to Work™ recertification
Chiesi Partnership Day 2023
Chiesi Open Day 2023: a day of sharing and discovery
Chiesi Group and Statkraft sign a 10-year renewable energy PPA
Inclusiveness, transparency and harmony: Chiesi Group introduces Human Rights Policy
Chiesi’s 2022 Sustainability Report: “Purpose First”
LEED certification: Chiesi's commitment for the sustainability of its buildings
A behavioral therapy app to close the access gap in COPD treatment
World Health Day: our commitment to provide Health For All
European Parliament vote on the revision of the EU’s legislative framework on F-gas: climate targets need innovative solutions
In 2022 Chiesi Group has been confirmed as the 1st Italian pharmaceutical company for the number of patents filed
What does it mean to be a B Corp? Chiesi's choice for a sustainable future
Rare Disease Day
The Chiesi Group and gender equality: a concrete achievement now certified by Bureau Veritas
Chiesi Group stands in solidarity with the people of #Turkiye and #Syria
The Alphabet of Sustainability
Discovering ESG Criterias (Environmental, Social and Governance), the Chiesi Group's committment
From cells to packaging
Chiesi’s new interim CEO
Energize Programme: a shared commitment to accelerate the adoption of renewable energy in the pharmaceutical sector
“Vendor Day”: the role of Chiesi Group’s Value Chain in shaping the future
Chiesi recognized by Biden Administration for its support and commitment to greater resilience in the fight against climate change
Fostering innovation for rare diseases in Europe: Chiesi supports the RDR Challenges Call
Giacomo Chiesi awarded by PharmaVoice100
A new EU proposal to protect people and planet by reducing F-gases
Chiesi Group joins Biden Administration pledge to decarbonize healthcare sector
CO2alizione Italia: not just a declaration of intent
The Art of Healing
Dear colleagues, it's showtime!
A musical manifesto to rewrite the future
Innovating for the health of the planet and people, starting from the little things
New record for Chiesi Group: in 2021 it’s confirmed top Italian pharmaceutical company for number of patents filed
The way towards a sustainable and resilient healthcare
Why biotech world needs new plants
World Prematurity Day: Chiesi’s commitment for the premature babies
Partners and suppliers protagonists of Chiesi Vendor Day 2021
“Helping the World to Breathe” - Chiesi Group among the protagonist of the ATS docuseries
Head of Chiesi Global Rare Diseases Recognized at RARE Champions of Hope Awards 2021
Chiesi wins the Diversity Leaders Award for the third consecutive year
The President Alberto Chiesi guest at the Farmindustria roadshow
Chiesi supports the São Paulo Declaration on Planetary Health
We ACT Day 2021: this year’s edition of Chiesi’s event for a sustainable future
We’re all aware of the climate crisis, but we’re not talking about its impact on respiratory health.
Chiesi Group is among "Sustainability Leaders 2021" companies in Italy
D&I Policy: a further demonstration of Chiesi's commitment
New record for the Chiesi Group, which is confirmed top Italian pharmaceutical company for number of patents filed
The Chiesi Group is on Twitter!
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
World Prematurity Day: Chiesi is at the forefront for preterm babies
Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder
Regeneration 20|3, the first global meeting to launch the program is in Parma on October 15 and 16.
Italy for Climate: Chiesi at the forefront for the future of Italy
CHIESI JOINS THE MOVEMENT OF ITALIAN B CORP COMPANIES “UNLOCK THE CHANGE”
The B Change: the Instant Book by Pharmastar is online
Chiesi Group and Holostem Terapie Avanzate announce transfer of Holoclar® from the Chiesi Group to Holostem
Happiness&Wellbeing: Maria Paola Chiesi at the Vatican workshop
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON
Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of INBRX-101 (AAT-Fc)
Chiesi Group Enters into License Agreement with Santhera for a treatment for LHON
Chiesi: “imprese per innovazione” award, Industry 4.0 and Sustainability Special Mentions
Chiesi enters in an exclusive global license agreement with TiumBio to develop innovative molecules for respiratory diseases
StartUp Health raises 31 million dollars from the Chiesi Group and a prominent group of other large pharmaceuticals companies and healthcare organizations
Chiesi signs a deal with StartUp Health: first investment in the digital area
Chiesi supports The Third Day exhibition, dedicated to the relationship between man and nature
Global Corporate Development : opening of new offices in Boston
Chiesi Digital Transformation - Digital Safari Workshop with David Orban
Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Chiesi certified Top Employer also for 2017
Chiesi is Top Employer again!
Alberto, Paolo and Andrea Chiesi winners of the “Entrepreneur of the year 2015” Award
Special Mention to Holoclar at the Italian Galeno Award
COPD indication for Foster pMDI
Double-digit growth and internal expansion for the Chiesi Group